European Annals of Allergy and Clinical Immunology THE OFFICIAL JOURNAL OF AAITO THE OFFICIAL JOURNAL OF SPAIC HOME PAGE

EDITORS IN CHIEF
L. Cecchi (Firenze - Italy)

P. Carreiro-Martins (Lisbon - Portugal)

 

HONORARY EDITOR
A. Sabbah (Angers - France)

 

ASSOCIATE EDITORS
R. Rodrigues Alves (Lisbon - Portugal)
A. Tedeschi (Milano - Italy)

 

EDITORIAL BOARD
M. Morais-Almeida (Lisbon - Portugal)
R. Asero (Milan - Italy)
M.B. Bilò (Ancona - Italy)
F. Bonifazi (Ancona - Italy)
L.M. Borrego (Lisbon - Portugal)

K. Brockow (München - Germany)
A.Ŕ. Cruz (Salvador - Brasil)
L. Delgado (Oporto - Portugal)
P. Demoly (Montpellier - France)
G. D'Amato (Napoli - Italy)
M. Drouet (Angers - France)
M. Fernandez-Rivas (Madrid - Spain)
A. Fiocchi (Milano - Italy)

J. Fonseca (Oporto - Portugal)
D. Macchia (Firenze - Italy)
F. Mastrandrea (Taranto - Italy)
M. Maurer (Berlin - Germany)
G. Moscato (Pavia - Italy)
A. Musarra (Reggio Calabria - Italy)
C. Nunes (Portimao - Portugal)
M. Olivieri (Verona - Italy)
P. Parronchi (Firenze - Italy)
G. Passalacqua (Genova - Italy)
G. Pauli (Strasbourg - France)
E. Pedro (Lisbon - Portugal)
A. Perino (Torino - Italy)
L.K. Poulsen (Copenaghen - Denmark)
O. Quercia (Faenza - Italy)
A. Romano (Roma - Italy)
E. Scala (Roma - Italy)
D. Solé (Sao Paulo - Brasil)
A. Todo Bom (Coimbra - Portugal)
S. Voltolini (Genova - Italy)

 

SCIENTIFIC COMMITTEE
L. Antonicelli (Italy)
A. Bener (Turkey)
H. Bazin (Belgium)
J. Bellanti (USA)
C. Geller-Bernstein (Israel)
M. Cugno (Italy)
B. David (France)
S. Durham (UK)
G.P. Girolomoni (Italy)
R. Jarish (Austria)
S.G.O. Johansson (Sweden)
F. Levi-Shaffer (Israel)
H. Lowenstein (Denmark)
J.L. Malo (Canada)
A.G. Palma-Carlos (Portugal)
G. Scadding (UK)
G. Scadding (UK)
E. Stevens (Belgium)
R. van Ree (Netherlands)

 

FOUNDER AND CORRESPONDING MEMBER
G.M. Halpern (USA)


*************************

Editors in Chief
Lorenzo Cecchi
Pedro Carreiro-Martins

Chief Business & Content Officer
Ludovico Baldessin

Publishing Editor

Greta Schincaglia

g.schincaglia@lswr.it
Ph. 0039 (0)2-88184.512


Production Manager

Walter Castiglione
w.castiglione@lswr.it
Ph. 0039 (0)2-88184.222

Sales
Stefano Busconi
dircom@lswr.it
Ph. 0039 (0)2-88184.404

Printing
Mccgraphics
Pol. Ind. Txirrita Maleo Pab 11
20100 Errenteria (Gipuzkoa), Spain

EDRA SpA
Via G. Spadolini, 7
20141 Milano - Italy
Ph. 0039 (0)2-88184.1
Fax 0039 (0)2-88184.301 
www.edizioniedra.it

Contents »

Clinical experience of a chronic urticaria university referral center


G. Andrade Coelho Dias gabrielaacdias@gmail.com 1, F. Cunha Coelho1, P. Filippo1, D. Lacerda Pedrazzi1, A.C. Nogueira Arraes1, M.I. Perelló1, F. Chigres Kuschnir1, E. Costa2

Show more: Authors information and Publication history

Doi
https://doi.org/10.23822/EurAnnACI.1764-1489.103

Summary
Objective.
Describe routine procedures, clinical profile and evolution of patients treated in a chronic urticaria (CU) reference center of a university hospital. Methods. Retrospective analysis of clinical records and database of CU patients registered between March 2011 and February 2016 in a reference center. Besides, demographic characteristics were recorded: disease duration, comorbidities, angioedema, thyroid lab tests, urticaria subtypes, provocation tests, UAS and CUQ2oL scores. Patients with 3 or more visits were included in analysis regarding the first and last visits to evaluate pharmacological treatment and differences of UAS/CUQ2oL scores, antihistamines (anti-H1) dosages and need of other medications, according urticaria subtypes. Results. During the study, 252 patients were attended, 200 with CU, including 162 women, median age 45 years (perc 25 - 75 = 27 - 58) and median duration of symptoms before diagnosis: 24 months (perc 25 - 75 = 9 - 60). Regarding the etiology, 166 (83%) patients had chronic spontaneous urticaria (CSU), 34 (17%) had isolated chronic inducible urticaria (CIndU), and 66 (33%) CSU with CIndU. Among the 123 patients followed up for 3 or more visits, first prescription to 106 (86.2%) patients was monotherapy with anti-H1, and associations with other medications were prescribed to 17 (13.8%). At the last visit, 94 (76.5%) received antihistamines, and 29 (23.5%) used associations. Patients with CSU + CIndU + ASST positive need more association of anti-H1 with other medications than patients with CSU + CIndU and only CIndU (÷2 = 7.998; p = 0.01). Between first and last visits CUQ2oL mean scores changed from 35.7 (± 21.9) to 22.6 (± 21.0) (Z = -4.833 p < 0.000). Conclusion. Most of the patients presented CSU, associated frequently with CIndU. All patients were treated with antihistamines and there was a great need for doses above standardized, and also for combination with other medications, with improved quality of life during the follow-up period.

Key words
chronic urticaria; treatment; antihistamines; urticaria activity score; quality of life